13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q4 2023. See the latest, Q2 2026 →
Reported value
$2.16B
+39% on the quarter before
Positions
44
2 new · 3 sold out
Top 10
88.3%
of the value
Est. gain
+$270.1M
on stocks held all quarter
Est. return
+20.3%
on those stocks since Q3 2023
Positions as of Dec 31, 2023, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q3 2023. Striped tiles are options.
Largest buys
Since Q3 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Dexcom Inc~$375.6MAdded · 3.9% → 21.2%+3,027,031 shares
- Revolution Medicines Inc~$152.0MNew · 0.0% → 7.0%+5,301,512 shares
- Verve Therapeutics Inc~$25.1MAdded · 9.0% → 8.0%+1,800,000 shares
- Neumora Therapeutics Inc.~$3.5MAdded · 0.2% → 0.3%+205,124 shares
- Science 37 Holdings Inc~$856,343New · 0.0% → 0.0%+160,364 shares
- Oscar Health Inc~$187,482Added · 5.2% → 0.7%+20,490 shares
Largest sells
Since Q3 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- UiPath~$174.7MCut · 15.5% → 8.1%−7,034,337 shares
- Eqrx Inc~$105.8MSold out · 6.8% → 0.0%−47,675,476 shares
- Science 37 Holdings Inc~$1.3MSold out · 0.1% → 0.0%−3,207,260 shares
- Evelo Biosciences Inc~$207,854Sold out · 0.0% → 0.0%−53,024 shares
Holdings
As of Dec 31, 2023. Changes are in shares against Sep 30, 2023, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dexcom IncCOM · shares +462% · price +33.0% | 21.2% | $456.9M | +$20.2M | ||||||||
| CrowdStrikeCL A · shares 0% · price +52.5% | 15.2% | $327.7M | +$112.9M | ||||||||
| UiPathCL A · shares −50% · price +45.2% | 8.1% | $174.7M | +$54.4M | ||||||||
| Verve Therapeutics IncCOM · shares +17% · price +5.1% | 8.0% | $172.1M | +$7.2M | ||||||||
| Gitlab IncCLASS A COM · shares 0% · price +39.2% | 7.7% | $166.7M | +$47.0M | ||||||||
| Revolution Medicines IncCOM · shares New | 7.0% | $152.0M | — | ||||||||
| Arm Holdings PlcSPONSORED ADR · shares 0% · price +40.4% | 6.8% | $147.3M | +$42.4M | ||||||||
| SnowflakeCL A · shares 0% · price +30.3% | 4.9% | $106.6M | +$24.8M | ||||||||
| Prime Medicine IncCOM · shares 0% · price −7.1% | 4.9% | $105.1M | −$8.1M | ||||||||
| Freshworks IncCLASS A COM · shares 0% · price +17.9% | 4.4% | $94.8M | +$14.4M | ||||||||
| Planet Labs PbcCOM CL A · shares 0% · price −5.0% | 3.7% | $78.9M | −$4.2M | ||||||||
| Invivyd IncCOM · shares 0% · price +131.8% | 1.0% | $22.4M | +$12.7M | ||||||||
| Relay Therapeutics IncCOM · shares 0% · price +30.9% | 0.80% | $17.3M | +$4.1M | ||||||||
| Oscar Health IncCL A · shares +1.3% · price −81.7% | 0.69% | $14.9M | −$65.9M | ||||||||
| Rapt Therapeutics IncCOM · shares 0% · price +49.5% | 0.62% | $13.4M | +$4.4M | ||||||||
| Sana Biotechnology IncCOM · shares 0% · price +5.4% | 0.53% | $11.5M | +$590,625 | ||||||||
| Lyell Immunopharma IncCOM · shares 0% · price +32.0% | 0.53% | $11.4M | +$2.8M | ||||||||
| Beam Therapeutics IncCOM · shares 0% · price +13.2% | 0.41% | $8.8M | +$1.0M | ||||||||
| Desktop Metal IncCOM CL A · shares 0% · price −48.6% | 0.38% | $8.3M | −$7.8M | ||||||||
| Monte Rosa Therapeutics IncCOM · shares 0% · price +18.0% | 0.38% | $8.3M | +$1.3M | ||||||||
| Illumina IncCOM · shares 0% · price +1.4% | 0.35% | $7.4M | +$104,801 | ||||||||
| Neumora Therapeutics Inc.COM · shares +103% · price +20.8% | 0.32% | $6.9M | +$586,849 | ||||||||
| Tscan Therapeutics IncCOM · shares 0% · price +127.7% | 0.29% | $6.3M | +$3.5M | ||||||||
| Barinthus Biotherapeutics PlADS · shares 0% · price +19.4% | 0.26% | $5.6M | +$908,187 | ||||||||
| Vera Therapeutics IncCL A · shares 0% · price +12.2% | 0.22% | $4.6M | +$503,639 | ||||||||
| Total · 44 positions | 100% | $2.16B | +$270.1M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q3 2023 to Q4 2023: 42 stocks held throughout, up $270.1M (+20.3%).
- CrowdStrike+$112.9M+53%
- UiPath+$54.4M+45%
- Gitlab Inc+$47.0M+39%
- Arm Holdings Plc+$42.4M+40%
- Snowflake+$24.8M+30%
- Benson Hill Inc−$2.5M−48%
- Planet Labs Pbc−$4.2M−5%
- Desktop Metal Inc−$7.8M−49%
- Prime Medicine Inc−$8.1M−7%
- Oscar Health Inc1:9 split−$65.9M−82%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out, 1 split read into the share counts.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |